Completed PHASE2 INTERVENTIONAL 2-arm NCT00089609

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

A Phase II Trial of Docetaxel, Thalidomide, Prednisone and Bevacizumab in Patients With Androgen-Independent Prostate Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Prostatic Neoplasms

Interventions Docetaxel Prednisone Thalidomide bevacizumab immunoenzyme technique laboratory biomarker analysis pharmacological study polymorphism analysis

Updated 8 times since 2017 Last updated: Mar 22, 2018 Started: Apr 19, 2005 Primary completion: Dec 31, 2011 Completion: Jan 9, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00089609, this PHASE2 trial focuses on Prostatic Neoplasms and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Dec 2017 — May 2018 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States